<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">21045814</PMID>
<DateCompleted>
<Year>2011</Year>
<Month>04</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1572-0241</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>106</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2011</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>The American journal of gastroenterology</Title>
<ISOAbbreviation>Am. J. Gastroenterol.</ISOAbbreviation>
</Journal>
<ArticleTitle>The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?</ArticleTitle>
<Pagination>
<MedlinePgn>199-212; quiz 213</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/ajg.2010.392</ELocationID>
<Abstract>
<AbstractText>The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical characteristics, previous response to other medical therapy, and comorbid conditions. Availability, reimbursement guidelines, and patient preferences guide the choice of first-line biological therapy for luminal Crohn's disease (CD). Infliximab (IFX) has the most extensive clinical trial data, but other biological agents (adalimumab (ADA), certolizumab pegol (CZP), and natalizumab (NAT)) appear to have similar benefits in CD. Steroid-refractory, steroid-dependent, or complex fistulizing CD are indications for starting biological therapy, after surgical drainage of any sepsis. For fistulizing CD, the efficacy of IFX for inducing fistula closure is best documented. Unique risks of NAT account for its labeling as a second-line biological agent in some countries. Patients who respond to induction therapy benefit from systematic re-treatment. The combination of IFX with azathioprine is better than monotherapy for induction of remission and mucosal healing up to 1 year in patients who are naïve to both agents. Whether this applies to other agents remains unknown. IFX is also effective for treatment-refractory, moderate, or severely active ulcerative colitis. Patients who have a diminished or loss of response to anti-tumor necrosis factor (TNF) therapy may respond to dose adjustment of the same agent or switching to another agent. Careful consideration should be given to the reasons for loss of response. There are insufficient data to make recommendations on when to stop anti-TNF therapy. Preliminary evidence suggests that a substantial proportion of patients in clinical remission for &gt;1 year, without signs of active inflammation can remain in remission after stopping treatment.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>D'Haens</LastName>
<ForeName>Geert R</ForeName>
<Initials>GR</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands. g.dhaens@amc.uva.nl</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Panaccione</LastName>
<ForeName>Remo</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Higgins</LastName>
<ForeName>Peter D R</ForeName>
<Initials>PD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vermeire</LastName>
<ForeName>Severine</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gassull</LastName>
<ForeName>Miquel</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chowers</LastName>
<ForeName>Yehuda</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hanauer</LastName>
<ForeName>Stephen B</ForeName>
<Initials>SB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Herfarth</LastName>
<ForeName>Hans</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hommes</LastName>
<ForeName>Daan W</ForeName>
<Initials>DW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kamm</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Löfberg</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Quary</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sands</LastName>
<ForeName>Bruce</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sood</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Watermeyer</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="N">
<LastName>Watermayer</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lashner</LastName>
<ForeName>Bret</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lémann</LastName>
<ForeName>Marc</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Plevy</LastName>
<ForeName>Scott</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Reinisch</LastName>
<ForeName>Walter</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schreiber</LastName>
<ForeName>Stefan</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Siegel</LastName>
<ForeName>Corey</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Targan</LastName>
<ForeName>Stephen</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Watanabe</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Feagan</LastName>
<ForeName>Brian</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sandborn</LastName>
<ForeName>William J</ForeName>
<Initials>WJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Colombel</LastName>
<ForeName>Jean Frédéric</ForeName>
<Initials>JF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Travis</LastName>
<ForeName>Simon</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2010</Year>
<Month>11</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Gastroenterol</MedlineTA>
<NlmUniqueID>0421030</NlmUniqueID>
<ISSNLinking>0002-9270</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005765">Gastrointestinal Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007140">Immunoglobulin Fab Fragments</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000069442">Natalizumab</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>3WJQ0SDW1A</RegistryNumber>
<NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>B72HH48FLU</RegistryNumber>
<NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>FYS6T7F842</RegistryNumber>
<NameOfSubstance UI="D000068879">Adalimumab</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>MRK240IY2L</RegistryNumber>
<NameOfSubstance UI="D001379">Azathioprine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>UMD07X179E</RegistryNumber>
<NameOfSubstance UI="D000068582">Certolizumab Pegol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="ErratumIn">
<RefSource>Am J Gastroenterol. 2011 Feb;106(2):375</RefSource>
<Note>Watermayer, G [corrected to Watermeyer, G]</Note>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>Am J Gastroenterol. 2011 Feb;106(2):225-7; quiz 228</RefSource>
<PMID Version="1">21301451</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000068879">Adalimumab</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000893">Anti-Inflammatory Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001379">Azathioprine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000068582">Certolizumab Pegol</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003092">Colitis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003424">Crohn Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005765">Gastrointestinal Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007140">Immunoglobulin Fab Fragments</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007166">Immunosuppressive Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000069285">Infliximab</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000069442">Natalizumab</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018579">Patient Selection</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011092">Polyethylene Glycols</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012074">Remission Induction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2010</Year>
<Month>11</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2010</Year>
<Month>11</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2011</Year>
<Month>4</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">21045814</ArticleId>
<ArticleId IdType="pii">ajg2010392</ArticleId>
<ArticleId IdType="doi">10.1038/ajg.2010.392</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>